Result of intravitreal aflibercept injection for myopic choroidal neovascularization

BMC Ophthalmology

Table 2 Clinical characteristics pertaining to all the patients at the baseline and 12 months after the administration of the primary aflibercept injection

Parameter	Median	IQR [range]	Min-Max	p
Median central foveal thickness (μm)
Baseline	285.50	41.5 [265–306.5]	222–437	0.009 ^a
12 months after aflibercept injection	249.00	54 [223–277]	188–466
BCVA (logMAR)
Baseline	0.700	0.5 [5–1.0]	0.30–1.78	0.001 ^b
Three months after aflibercept injection	0.39	0.3 [0.2–0.5]	0.16–0.70
Twelve months after aflibercept injection	0.300	0.28 [0.16–0.44]	0.05–0.70

BCVA best-corrected visual acuity, IQR interquartile range, Max maximum, Min minimum
^a Wilcoxon signed-rank test
^b Friedman two-way ANOVA test

ISSN: 1471-2415